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Noribogaine is the long-lived human metabolite of the anti-addictive substance ibogaine. Noribogaine
efﬁcaciously reaches the brain with concentrations up to 20 mM after acute therapeutic dose of 40 mg/kg
ibogaine in animals. Noribogaine displays atypical opioid-like components in vivo, anti-addictive effects
and potent modulatory properties of the tolerance to opiates for which the mode of action remained
uncharacterized thus far. Our binding experiments and computational simulations indicate that nor-
ibogaine may bind to the orthosteric morphinan binding site of the opioid receptors. Functional activities
of noribogaine at G-protein and non G-protein pathways of the mu and kappa opioid receptors were
characterized. Noribogaine was a weak mu antagonist with a functional inhibition constants (Ke) of
20 mM at the G-protein and b-arrestin signaling pathways. Conversely, noribogaine was a G-protein
biased kappa agonist 75% as efﬁcacious as dynorphin A at stimulating GDP-GTP exchange (EC50 ¼ 9 mM)
but only 12% as efﬁcacious at recruiting b-arrestin, which could contribute to the lack of dysphoric effects
of noribogaine. In turn, noribogaine functionally inhibited dynorphin-induced kappa b-arrestin
recruitment and was more potent than its G-protein agonistic activity with an IC50 of 1 mM. This biased
agonist/antagonist pharmacology is unique to noribogaine in comparison to various other ligands
including ibogaine, 18-MC, nalmefene, and 60-GNTI. We predict noribogaine to promote certain analgesic
effects as well as anti-addictive effects at effective concentrations >1 mM in the brain. Because elevated
levels of dynorphins are commonly observed and correlated with anxiety, dysphoric effects, and
decreased dopaminergic tone, a therapeutically relevant functional inhibition bias to endogenously
released dynorphins by noribogaine might be worthy of consideration for treating anxiety and substance
related disorders.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).G protein-coupled receptor;
PRD, d-opioid receptor; Nor-
4, Gly-ol5]-enkephalin.
re@gmail.com (E.L. Maillet).
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Noribogaine (Fig. 1) is the primary human metabolite of ibo-
gaine (Obach et al., 1998), an alkaloid derived from the African
shrub, iboga (Tabernanthe iboga). The therapeutic and oneiro-
phrenic properties of iboga roots are known for centuries innder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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medicine and for ceremonial purposes (Goutarel et al., 1993;
Samorini, 1995). Naranjo, in collaboration with Bocher, issued a
patent in 1969 based on 54 clinical cases featuring the usefulness of
ibogaine for psychotherapy and anti-drug purposes (Bocher and
Naranjo, 1969). A few decades later, the beneﬁts of iboga (ibo-
gaine) in the treatment of addiction for multiple drugs of abuse
were highlighted by different groups (Alper et al., 1999; Mash et al.,
1998; Sheppard, 1994). Preclinical studies show that ibogaine is a
polypharmacological drug that can reduce self-administration to
many drugs of abuse in rodents, including cocaine, morphine,
heroin, alcohol, and nicotine; and further experimentation in
humans supported its usefulness to treat addiction (Alper, 2001;
Baumann et al., 2001a; Freedlander, 2003; Maciulaitis et al.,
2008; Mash et al., 2000; Popik et al., 1995).
Noribogaine displayed a slow pharmacokinetic clearance rate in
humans, being detected for several days in blood after ibogaine
ingestion, and was proposed to be responsible for many of the
human in vivo effects seen after ibogaine therapy (Mash et al.,
2000). Noribogaine produced ibogaine-like anti-addictive effects
in animals and the systemic administration of noribogaine induced
long-lasting decrease of morphine and cocaine self-administration
(Glick et al., 1996; Mash and Schenk, 1996). Noribogaine also
decreased ethanol self-administration (Rezvani et al., 1995) and
nicotine self-administration in rats (Chang et al., 2015). The brain
levels of noribogaine in female/male rats were approximately 20/
13, 10/7 and 0.8/0.1 mM at 1, 5, and 19 h after intra-peritoneal in-
jection of 40 mg/kg ibogaine whereas plasma levels were 10e20
fold less (Pearl et al., 1997). This indicated that noribogaine had
excellent drug permeability across the bloodebrain barrier and
reached high levels in the brain. Unlike ibogaine, noribogaine did
not produce tremors and ataxia in rodents (Baumann et al., 2001b),Fig. 1. Structures of noribogaine, and other mu and kappa opioids ligands tested in th
norphine, naloxone, noribogaine, ibogaine, morphine, norbinaltorphimine (nor-BNI), 18-met
Agonists (red), partial agonists (purple), and antagonists (green) are arranged in the diagr
overlapping region have afﬁnity for both subtypes. (For interpretation of the references tosuggesting that it is better tolerated than its parent compound and
a better drug candidate for clinical development. Recently, a study
performed in healthy volunteers indicated that single oral doses of
noribogaine from 3 to 60 mg were safe and well tolerated (Glue
et al., 2015).
Of particular interest with regards to their acknowledged roles
in modulating opiate dependence are ibogaine and noribogaine's
effects on the opioid system. In addition to effects on the pursuit
and administration of drug of abuse, these drugs were shown to
modulate the analgesic power and the development of physical
tolerance to morphine. Pre-administration of noribogaine (40 mg/
kg, 19 h) had a moderate but detectable effect of potentiation on
both basal nociception and morphine-induced analgesia (Bagal
et al., 1996). When noribogaine (40 mg/kg) was co-administered
with 4 mg/kg morphine, it ampliﬁed the duration of morphine-
induced analgesia (Bagal et al., 1996). Noribogaine (40 mg/kg)
enhanced anti-nociception when added to morphine but did not
enhance anti-nociception when combined with U50,488 (kappa
opioid agonist) or DPDPE (delta opioid agonist) (Bhargava et al.,
1997). At lower doses of 10e20 mg/kg, noribogaine has also been
shown to greatly potentiate (or restore) morphine anti-nociceptive
activity in morphine-tolerant mice but remained inactive in naïve
mice (Sunder Sharma and Bhargava, 1998). Finally, noribogaine was
shown to prevent the development of tolerance to the analgesic
effects of morphine (Bhargava and Cao, 1997). The mode of action
for these effects, as well as the anti-addictive effects, remained
largely uncharacterized thus far.
Noribogaine has principal known binding afﬁnities to the opioid
receptors, the nicotinic acetylcholine receptors (Maillet et al., sub-
mitted manuscript), and the SERT and DAT transporters, but mar-
ginal afﬁnities to NMDA, sigma 2 and 5-HT2 receptors in
comparison to the parent compound ibogaine (Baumann et al.,is study. [Met]-enkephalin, [D-Ala2, N-MePhe4, Gly-ol]-enkephalin (DAMGO), bupre-
hoxycoronaridine (18-MC), dynorphin A, nalmefene, 6'-guanidinonaltrindole (6’-GNTI).
am according to their afﬁnities for either the m or k opioid receptor. Structures in the
colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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1996). Ibogaine and noribogaine were found to have potencies in
the micro-to high nano-molar range for the opioid receptors (Pearl
et al., 1995) but they do not appear to be conventional opioid ag-
onists or antagonists. Noribogaine, and ibogaine to a lesser extent,
were shown to induce naloxone-sensitive GTPgS binding in rat
brain preparations (Pablo and Mash, 1998). These drugs however
did not induce conditioned place preference like mu agonists or
conditioned place aversion like kappa agonists or mu antagonists
(Skoubis et al., 2001) in animals ((Parker et al., 1995) and unpub-
lished results). In addition, neither morphine nor the kappa agonist
U50,488 substituted for the discriminative stimulus of noribogaine
treatment in rats (Helsley et al., 1998) (Zubaran et al., 1999). In a
sense, noribogaine was neither a mu or a kappa opioid agonist or
antagonist in vivo and it remained largely unclear what the speciﬁc
roles and activities of noribogaine at the opioid receptors would be
in relation to physiological outputs.
To address this gap of knowledge, we carried out a pharmaco-
logical study to characterize noribogaine to the mu (OPRM) and the
kappa (OPRK) opioid receptors. We performed comprehensive
in vitro and in silico experimental designs encompassing both
binding and functional assays for G-protein signaling using GTPgS
binding stimulation, b-arrestin signaling using protein recruitment
assay, in addition to performing docking simulations. We then
compared the pharmacology of noribogaine to its parent drug
ibogaine, the synthetic indole alkaloid 18-methoxycoronaridine
(18-MC) (Glick et al., 2000), and a series a speciﬁc opioid ligands
including the kappa partial agonist nalmefene (Bart et al., 2005),
and the biased kappa agonist 60-GNTI (Rives et al., 2012) (Fig.1). Our
study reveals an atypical biased agonism of noribogaine at the
kappa receptors and provides important pharmacological basis for
its mechanism of action as a drug therapeutic.
2. Materials and methods
2.1. Materials
[Phenyl-3, 4-3H]-U-69,593 (43.6 Ci/mmol), [Tyrosyl-3, 5-3H(N)]-
DAMGO ([D-Ala2, N-MePhe4, Gly5-ol]-enkephalin) (50 Ci/mmol)
and [35S]GTPgS (Guanosine 500-(gamma-thio)triphosphate)
(1250 Ci/mmol) were purchased from PerkinElmer Life Sciences
(Boston, MA). U69,593, naloxone, nor-binaltorphimine (nor-BNI),
morphine, nalmefene, dynorphin A, DAMGO, GTPgS, GDP and all
buffer constituents were purchased from SigmaeAldrich Corp (St.
Louis, MO). CHOeK1 cell lines expressing human opioid receptors
were provided by Dr. Toll at Torrey Pines Institute (Port St. Lucie,
FL). Ibogaine was provided by Dr. Mash at the University of Miami
(Miami, FL). 18-methoxycoronaridine (18-MC) was purchased from
Obiter Research LLC (Champaign, IL). Noribogaine hydrochloride
was purchased from Sigma Aldrich Chemie GmbH (Buchs,
Switzerland).
2.2. Membrane preparation
Membrane preparations of rat midbrain tissues were purchased
from Chantest (Cleveland, OH). Membrane preparation of human
OPRK CHOeK1 cells were purchased from PerkinElmer Life Sci-
ences (Boston, MA) and membranes of human OPRM CHOeK1 cells
were prepared as described below. Adherent cells were harvested
on ice, with cold PBS and a cell scraper, pelleted and frozen
at 80 C overnight. Cell lysis was performed at 4 C in 50 mM Tris
(pH 7), 2.5 mM EDTA and cOmplete protease inhibitor cocktail
(cOmplete, F. Hoffmann-La Roche Ltd). Cells were homogenized
with a polytron, centrifuged at 2500 rpm for 10 min at 4 C and the
supernatant was recovered. The process was repeated once.Supernatant was centrifuged at 21,000 rpm for 90 min at 4 C and
pellets were re-suspended in 50 mM Tris (pH 7) and 0.32 M su-
crose. Total protein concentration was determined using a Ther-
moScientiﬁc NanoDrop spectrophotometer or by Bradford assay.
Membrane samples were stored at 80 C at 1e5 mg/mL protein
concentration. Membranes from brain tissues were stored in
50 mM Tris (pH 7), 1 mM EDTA and 0.32 M sucrose with protease
inhibitor cocktail.
2.3. Radioligand binding
Competitive binding experiments were performed using con-
ditions recommended by the supplier (Perkin Elmer). Membranes
were thawed on ice and diluted in binding buffer 50 mM Tris-HCl
pH 7.4, 5 mM MgCl2 at 5 mg of membrane per reaction. Competi-
tion binding assays were performed in 500 mL total volume con-
taining [3H]U69,593 (0.88 nM) for OPRK membranes or [3H]
DAMGO (0.75 nM) for OPRM membranes in the presence of
increasing concentrations of each unlabeled drug (noribogaine,
ibogaine,18-MC, U69,593, morphine, DAMGO, naloxone) for 60min
at 25 C. Nonspeciﬁc binding was deﬁned in the presence of 1 mM
naloxone. Bound and free radiolabeled ligands were separated by
ﬁltration using a MicroBeta FilterMate-96 Harvester and wash
6  1 mL with ice cold wash buffer (50 mM Tris-HCl pH 7.4) over
GF/B ﬁlter (presoaked in 0.5% BSA) (Perkin Elmer, Waltham, MA).
Radioactivity counts were determined using Perkin Elmer
MicroBeta microplate counter with scintillation cocktail Micro-
Scint-20™ according to manufacturer recommendations. Data
were collected and the half maximal inhibitory concentration (IC50)
and apparent binding afﬁnity (Ki) for all data sets were calculated
with GraphPad Prism 5.04.
2.4. [35S]GTPgS binding assay
[35S]GTPgS binding to Ga proteins was determined using a
procedure modiﬁed from (Toll et al., 1998) and carried out in a 96-
well format. Cell membranes (10 mg per reaction) were incubated in
a binding buffer (20 mM HEPES, pH 7.4, 100 mM NaCl, 10 mM
MgCl2x6H2O, 0.2% bovine serum albumin, and GDP 10 mM, pH 7.4)
containing 80 pM [35S]GTPgS and varying concentrations of opioid
agonists (U69,593, DAMGO, morphine, dynorphin A, nalmefene, or
noribogaine) in a total volume of 100 mL for 60 min at 25 C.
Membranes were pre-incubated with the GDP for 15 min on ice
prior to the addition of ligands. Antagonists were added to the
membrane solution 20 min prior the addition of the agonist, and
[35S]GTPgS was added 5 min after the agonist. Non-speciﬁc and
basal levels of GTPgS binding were evaluated by using 10 mM cold
GTPgS or binding buffer, respectively. Bound and free [35S]GTPgS
were separated by ﬁltration using a MicroBeta FilterMate-96
Harvester and wash 4  1 mL with ice cold wash buffer (20 mM
Tris, pH 7.4, and 2.5 mMMgCl2x6H2O, pH 7.4) over presoaked GF/B
ﬁlter (Perkin Elmer, Waltham, MA). Radioactivity counts were
determined using Perkin Elmer MicroBeta microplate counter with
scintillation cocktail MicroScint-20™ according to manufacturer
recommendations. Data were collected and the half maximal
effective concentration (EC50) andmaximal responses (Emax) values
were calculated using non-linear regression with GraphPad Prism
5.04.
2.5. b-Arrestin-2 recruitment assay
The PathHunter enzyme complementation Arrestin-2 Recruit-
ment assays were performed at DiscoveRx Corporation (Fremont,
CA) and at the DemeRx Laboratory (Miami, FL). This assay utilized
CHOeK1 cells stably transfected to overexpress b-arrestin-2 fused
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(NM_000912.3, encoding human KOR) or human OPRM gene
(NM_000914.3, encoding human MOR). Brieﬂy, when b-arrestin-2
travels to active receptor, the complementary b-galactosidase
fragments fused to the receptor and b-arrestin interact to form a
functional enzyme with activity that is detected by chem-
iluminescence. For all in vitro assays, data were normalized as a
percentage of control agonist responses, typically deﬁned by
dynorphin A stimulated activity in the OPRK assays, and [met]-
enkephalin stimulated activity in the OPRM assays. For agonist
concentration-response experiments, cells were treated with test
compound for 180 min prior to assessment of enzyme comple-
mentation. For antagonist concentration-inhibition experiments,
the cells were incubatedwith the test compound for 30min prior to
agonist addition.
2.6. Data analysis
The IC50 and Ki values for ligands in the radioactive binding
assays were determined by ﬁtting competition binding data of
individual experiments normalized to buffer (total binding) and
1 mM naloxone (nonspeciﬁc binding) to a single site competition
model in GraphPad Prism 5.04 using the transformation of Cheng
and Prusoff (Cheng and Prusoff, 1973) (CFeq): Ki ¼ IC50/(1 þ[S]/
Km), where [S] is the concentration of agonist and Km is the Ki
value for [3H]U69,593 and [3H]DAMGO determined by homolo-
gous competition. The EC50 and EMax values to agonists for [35S]
GTPgS binding and b-arrestin-2 translocation were determined by
ﬁtting data from individual experiments to sigmoidal
concentration-response curves with variable slope in GraphPad
Prism 5.04. IMax was calculated as the % of inhibition from the EMax
of the full agonist U69,593 (OPRK) or DAMGO (OPRM) to the basal
signal. Functional inhibitory potency (Ke) values for agonist
concentration-response displacement experiments were calcu-
lated using the Gaddum/Schild EC50 shift calculation in GraphPad
Prism or with the following equation: Ke¼ [A]/(DR-1), where [A] is
the concentration of antagonist and DR is the ratio of the EC50 for
an agonist in the presence and absence of the antagonist. Ke values
from concentration-inhibition experiments were calculatedwith a
modiﬁed CFeq: Ke ¼ IC50/(1þ[S]/EC50) where [S] is the concen-
tration of agonist, EC50 is the functional potency of the agonist, and
IC50 is the half-maximal inhibition concentration of antagonist.
Final mean and S.E. were calculated using individual values from
each experiment.
Activation coupling efﬁciency (e-coupling) values describe the
relationship between the apparent binding afﬁnity Ki versus the
apparent functional potency EC50 of a given agonist ligand and used
the equation pKi-pEC50 where “p” represents a elog10 trans-
formation. For the functional inhibitory components of antagonists
and partial agonists, e-coupling represents the relationship be-
tween the Ki versus the Ke of a given inhibitor against a given
agonist ([ϞDyn-A] and used the equation pKi-pKe. Efﬁcacy efﬁ-
ciency (e-signal) values describe the ratio of the EMax to a tested
ligand versus the EMax to reference full agonist dynorphin A (or
U69,593) for OPRK and DAMGO or [met]-enkephalin for OPRM and
used the equation EMax(test compound)/EMax(control agonist). For
inhibitory ligands, e-signal was calculated using maximal level of
inhibition (Imax) normalized from 0 (basal, buffer) to 1 (agonist
without inhibitor).
Bias-coupling (quantiﬁcation of pathway bias for the coupling
efﬁciency) was calculated by dividing the EC50 (activation bias) or
the Ke (inhibition bias) issued from the G-protein pathway assays
by those issued from b-arrestin pathway assays for a given ligand,
rectiﬁed by the intrinsic functional assay efﬁciency (deﬁned as the
average of the cluster values of functional coupling efﬁciency oftypical full agonists and antagonists). The intrinsic functional assay
efﬁciency is dependent of the assay and the experimental condi-
tions (for instance the GDP content in the GTPgS assay, the tem-
perature and time of incubation) and independent of the ligands
binding afﬁnity (the potency ranking of high to low afﬁnity ligands
remain constant regardless of the assay conditions). Bias-efﬁcacy in
favor of the G-protein pathway was evaluated by dividing the
functional activation and the functional inhibition maximum re-
sponses (e-signal) from the G-protein pathway by the beta-arrestin
pathway assays for a given ligand.
2.7. m-Opioid receptor noribogaine binding model
Weused themouse m-opioid receptor OPRM co-crystal structure
available in the Protein Data Bank (PDB), PDB accession 4dkl, Uni-
prot accession P42866. Themouse OPRM has 94% (global) sequence
identity to the corresponding human receptor (Uniprot accession
P35372) and all residues in the binding site are identical. The re-
ceptor was crystallized as a fusion protein (OPRMeT4L) with an
irreversible morphine antagonist ligand (bound to Lys233, PDB
numbering). All simulations were performed using the Schrodinger
2014.2 and Desmond 2014.2 software suite. For initial docking
studies we imported the PDB ﬁle into Maestro 9.5 (Schrodinger)
and ran the standard protein preparation workﬂow to assign bond
orders and clean up the structure including hydrogen bond opti-
mization and constrained minimization. In the preparation process
missing side chains were added using Prime. The fusion proteinwas
manually cut and removed between residues Val262 and Glu270 to
leave just the GPCR transmembrane domain; the cut residues were
capped as primary amide (C-terminal) and acetate (N-terminal). A
(non-covalent) ligand entry (separate from the chain) was manu-
ally created in Maestro. The resulting protein complex was again
processed via the protein preparationworkﬂow. A docking grid was
created around the co-crystal ligand using Glide (standard set-
tings). Several small molecules including the morphinan co-crystal
ligand (unbound), ibogaine and noribogaine were imported as 2D
SDF into Maestro and 3D structure representations were generated
using LigPrep (default settings); two representations (inverted at
the tertiary bridgehead nitrogen) were generated for each ligand.
These were docked using Glide SP (standard settings except
keeping 5 poses per compound out of 30 for post-minimization).
The docked morphinan ligand reproduced the co-crystal almost
perfectly. This docked complex was then optimized using Prime
Reﬁne ProteineLigand complex (default settings). This complex
was then used to generate another docking grid using Glide (default
settings around the ligand) followed by Glide SP docking of the
prepared ligands. In these results, the top poses of noribogaine and
ibogaine aligned well the morphinan antagonist (hydrophobic
ibogaine and noribogaine bicyclic system and ethyl substituent
with morphinan cyclopropyl residues and the positively charged
tertiary amines, which all form a hydrogen bond to the site chain of
Asp147). The m-OR noribogaine docking complex was then used in a
12 ns molecular dynamics (MD) simulation. The MD system gen-
eration and simulations were performed in Desmond using an all
atom system with a membrane model and explicit water model
(ASP). The Desmond software automatically sets up the systems
(adjust charges, adds water molecules) and performs several
rounds of minimization and short simulations before the 12 ns
production run. MD was run on the Pegasus 2 cluster at the Center
for Computational Science at the University of Miami (http://ccs.
miami.edu/hpc/) using 48 processors and completed in less than
19 h. Simulation analysis was performed using the Desmond tra-
jectory analysis software. A representative frame with these most
prevalent interactions throughout the simulation was extracted
from the trajectory, processed via protein preparation (including
E.L. Maillet et al. / Neuropharmacology 99 (2015) 675e688 679constrained minimization) to remove overlapping atoms, and
visualized using PyMol.
3. Results
3.1. Apparent binding afﬁnities of noribogaine to OPRM and OPRK
Competitive inhibition of [3H]-U69,593 to human OPRK and of
[3H]-DAMGO to human OPRM by noribogaine was conducted and
compared to ibogaine, 18-MC, and various control ligands (Fig. 1,
Table 1). Noribogaine exhibited the highest apparent afﬁnity for
OPRK with a Ki value of 720 ± 128 nM. At OPRK, ibogaine displayed
a Ki of 3.68 ± 0.22 mM, while 18-MC had a Ki a 1.84 ± 0.12 mM. At the
OPRM, noribogaine displayed a Ki of 1.52 ± 0.3 mM, while ibogaine
and 18-MC Ki values were 6.92 ± 0.83 mM and 2.26 ± 0.35 mM
respectively. Values of both noribogaine and ibogaine for the hu-
man OPRM/K receptors were comparable to that of the calf OPRM
and OPRK receptors (1.52 and 0.96 mM, Table 1) where noribogaine
was also previously shown to have ~30-fold less afﬁnity at OPRD
than at OPRK (Pearl et al., 1995). In our assays, 18-MC had no OPRM
preferential binding with a DpKi of 0.1, contrary to the previously
reported 5-fold selectivity (DpKi ¼ 0.7) for OPRM over OPRK
(Glick et al., 2000). Experimental values, historical values from the
literature, and control ligands, are displayed in Table 1 for agonists,
partial agonists, and antagonists used in this study.
3.2. Noribogaine is agonist of the OPRK G-protein pathway
[35S]GTPgS binding to membrane preparations of CHO cells
stably transfected with OPRK was examined in response to nor-
ibogaine, ibogaine, morphine, and nalmefene drug treatment andTable 1
Binding afﬁnity of noribogaine and other drugs at the human mu (OPRM) and kapp
Values for control ligands morphine, naloxone DAMGO, U69,593, dynorphin A, [met]-enk
literature. Speciﬁcity for the OPRK receptor was evaluated using the equation DpKi ¼ pKi(
(Huang et al., 2001, Li et al., 1993, Raynor et al., 1994, Sharma et al., 2001).the activation of the G-protein pathway by kappa agonists was
measured (Fig. 2A). The prototypical full agonist, U69,593, and the
endogenous ultra-potent agonist, dynorphin A, were used as
controls for OPRK function. Calculated EC50 and EMax values are
enumerated in Table 2. Noribogaine was a partial agonist at
stimulating [35S]GTPgS binding to OPRK with an EMax of 72 ± 3.8%
of U69,593, and an EC50 of 8.75 ± 1.09 mM (Fig. 2B, Table 2A).
Ibogaine displayed a notably lower agonist efﬁcacy than nor-
ibogaine at OPRK with an EMax of 18 ± 1.4%, while 18-MC failed to
stimulate [35S]GTPgS binding to OPRK. In our assays, morphine
and dynorphin A displayed EMax values of 91 ± 7% and 94 ± 7%
respectively, and nalmefene, a partial agonist of OPRK, maximally
stimulated at 35 ± 4.7%, which is similar to formally reported
values (Bart et al., 2005). Noribogaine stimulation of [35S]GTPgS
binding was also observed in membrane preparations from rat
midbrain tissues and this signal was nor-BNI-sensitive, conﬁrming
the agonist activity of noribogaine in native brain tissues (data not
shown).
The apparent coupling efﬁciencies of agonists DAMGO, U69,593,
morphine, dynorphin A, nalmefene, 60-GNTI, noribogaine and
ibogaine at the G-protein pathway were calculated (pKi e pEC50)
and found to be congruent with EC50 values shifted by ~1 log in
comparison to apparent afﬁnity Ki for all agonists (Tables 2A and 3).
The activation coupling efﬁciency of dynorphin A (0.6, this work)
and 60-GNTI (0.2, (Schmid et al., 2013)) were superior to other ag-
onists in this assay, indicating that a lower fraction of bound re-
ceptors was sufﬁcient to activate the pathway toward its maximal
efﬁciency. Conversely, the hillslope for dynorphin A concentration
response curves was below 1 (~0.7), indicating slower kinetics and
probably a longer residence time in the receptor active conforma-
tions, producing the observed heightened coupling efﬁciency.a (OPRK) opioid receptors. Ki values of noribogaine, ibogaine, and 18-MC (n  3).
ephalin, nalmefene, and buprenorphine were determined and/or gathered from the
OPRK)- pKi(OPRM). Agonists (red), partial agonists (purple), and antagonists (green).
Fig. 2. Noribogaine G-protein agonist activity at the kappa opioid receptor (OPRK). (A) CHOeK1 cell membrane preparations expressing human OPRK receptors were stimulated
with increasing concentrations of agonist (DAMGO, morphine: MOR, nalmefene: NALM) and test compound (noribogaine: NORI, ibogaine: IBO; 18-MC) in a [35S]GTPgS binding
assay. Mean ± SE of EC50, EMax, and Ke values from up to 10 experiments are shown in Table 2. (B) EC50 shifts of noribogaine and dynorphin A were produced by pre-incubating
antagonists (naloxone: NALO; nalmefene: NALM; NorBNI) at 30, 3, and 5 nM respectively. Functional inhibition constants (Ke) of antagonists were calculated and are shown in
Table 3. Data points used for the non-linear regression analysis ﬁgures (A and B) are shown as the mean ± SEM of each representative experiment(s).
E.L. Maillet et al. / Neuropharmacology 99 (2015) 675e6886803.3. Common kappa antagonists competitively compete with
noribogaine
Inhibitory effects of kappa antagonists naloxone, nor-BNI, 18-
MC, and the partial agonist nalmefene on the agonist-induced
[35S]GTPgS binding by full or partial agonists dynorphin A,
U69,593, morphine, noribogaine and nalmefene were investigated.
Concentration-response curve shifts of agonists were gathered in
the absence and presence of ﬁxed antagonist concentration (30 nM
naloxone, 5 nM nor-BNI, 100 mM 18-MC, and 3 nM nalmefene) or in
some instances with iterative concentrations of the antagonist
(Fig. 2B, Table 3).
All antagonists tested right-shifted the concentration-response
curves of noribogaine, dynorphin A, morphine or U69,593 in a
concentration-dependent manner. This ﬁnding is consistent withTable 2
A/B:Noribogainemodulation of [35S]GTPgS binding (A) and b-Arrestin 2 recruitment (
the functional activation constant (EC50) of tested ligands dynorphin A (Dyn-A), U69,59
measured using non-linear regression analysis. The functional inhibition constant (Ke) for
1), where DR is the ratio of the agonist EC50 in the presence and the absence of inhibito
modiﬁed Cheng-Prusoff equation: Ke ¼ [IC50]/(1 þ[agonist]/EC50). Coupling efﬁciency (e-c
versus the EC50 or the functional inhibition potency (Ke) of a given ligand and used th
[Ϟagonist] represents the agonist used to test inhibitory compounds. Outliers in comparis
naloxone (inhibition) are underlined. Data are shown as the mean ± SE of (n) experimen
OPRK pKi [35S]-GTPgS binding
Activation
Ligands\outputs EMax in % ± s.e. (n) EC50 in nM ± s.e
Dynorphin A 10.3 94 ± 7 (3) 0.18 ± 0.04 (6)
U69,593 9.2 100 (9) 7.25 ± 0.9 (9)
Morphine 7.3 91 ± 7 (3) 434 ± 67 (4)
Noribogaine 6.1 72 ± 3.8 (14) 8749 ± 1092 (10
60-GNTIa 8.9 37 ± 2 2.1 ± 0.5
Nalmefene 10.1 35 ± 4.7 (3) 0.69 ± 0.14 (3)
Ibogaine 5.4 18 ± 1.4 (2) ~12000 (2)
18-MC 5.7 <5 (2) n/q
Nor-BNI 10.4 <5 n/q
Naloxone 8.6 ~10 n/q
PathHunter® b-arrestin recruitment
Dynorphin A 10.3 100 11 ± 2 (3)
U69,593a 9.2 100 59
Noribogaine 6.1 13 ± 3 (1) ~110 (1)
60-GNTIa 8.9 12 ± 3 5.9 ± 3.3
Nalmefene 10.1 31 ± 2 (1) ~0.3 (1)
Ibogaine 5.4 ~21 (1)
18-MC 5.7 ~12 (1)
Nor-BNI 10.4 <5 n/q
n/q non-quantiﬁable. n/d not determined.
a 60-GNTI values are from Schmid et al. (2013) and Ke was calculated from a [ϞU69,59these ligands being surmountable competitors of the noribogaine
and other tested agonists' binding site. Functional inhibition con-
stants (Ke) of the antagonists are shown in Table 3 with the
assumption of ideal conditions of competitiveness and equilibrium.
In all instances, the functional inhibition constants for these in-
hibitors were close to their Ki, regardless of the agonist they were
competing with, indicating that noribogaine was no different than
other agonists tested.
3.4. Noribogaine is an atypically weak functional competitor of
other kappa agonists in the [35S]GTPgS binding assay
Nalmefene is a partial agonist and can compete as a rival agonist
against more efﬁcacious agonists and inhibits their response up to
the reduced efﬁcacy of nalmefene itself, a pharmacologicallyB) in CHOeK1 stably expressing human OPRK. Themaximal stimulation (EMax) and
3, morphine, noribogaine, nalmefene, ibogaine, 18-MC, nor-BNI, and naloxone were
GTPgS assay was calculated using EC50 shifts with the equation: Ke¼ [Inhibitor]/(DR-
r or from concentration-inhibition curves in the presence of agonist at EC80 using a
oupling, e-cpl) indicated the relationship between the apparent binding afﬁnity (Ki)
e equations p(Ki/EC50) and p(Ki/Ke), where p represents a elog10 transformation.
on to reference compounds dynorphin A and U69,593 (activation), and nor-BNI and
ts.
Inhibition [ϞDyn-A]
. (n) pEC50/[e-cpl] Ke in nM ± s.e. (n) pKe / [e-cpl]
9.7/[0.6] n/q n/q
8.1/[1.1] n/q n/q
6.4/[0.9] n/q n/q
) 5.1/[1.0] 39797 ± 15560 (2) 4.4/[1.7]
8.7/[0.2] 0.18 9.7/[0.8]
9.2/[0.9] 0.077 ± 0.016 (4) 10.1/[0]
~4.9/[0.5] 6803 ± 250 (2) 5.2/[0.2]
n/q 2222 ± 257 (4) 5.6/[0.1]
n/q 0.029 ± 0.004 (7) 10.5/[0.1]
n/q 4.85 ± 0.95 (5) 8.3/[0.3]
8.0/[2.3] n/q n/q
7.2/[2.0] n/q n/q
~7/[0.9] Non-competitive
IC50 ¼ 1000 ± 160 (5)
6/[0.1]
8.2/[0.7] 0.56 9.3/[0.4]
9.5/[0.6] 0.32 9.5/[0.6]
~11212 5/[0.4]
> ~10303 5/[0.7]
n/q 0.13 ± 0.006 (3) 9.9/[0.5]
3] IC50 value.
Table 3
Functional inhibition constants Ke of noribogaine and other ligands against agonist-induced [35S]GTPgS binding in CHOeK1 stably expressing human OPRK. Ke values
collected from the non-linear regression analysis of concentration-response EC50-shift experimental designs of 3e7 experiments are shown as the mean ± SE in nM. [Ϟagonist]
represents the agonist used to test inhibitory compounds. Italic value represents the estimate of a hypothetical functional activation constant of designated agonist in the
presence of other agonists. Outliers are underlined. Graphical representation of Ke values against dynorphin A is shown in Fig. 3C.
Antagonists & rival agonists [ϞAgonists]
U69,593 Dynorphin A Morphine Noribogaine Nalmefene Ki EC50
U69,593 n/q n/q n/d 0.4 4 0.9 7.3
Dynorphin A n/q n/q n/q 0.003 0.1 0.05 0.18
Morphine n/d n/a n/q 74 270 47 434
Noribogaine 12e3 ± 0.8e3 40e3 ± 16e3 15e3 ± 4e3 n/q 24e3 700 8.7e3
Nalmefene 0.14 ± 0.04 0.077 ± 0.016 0.11 ± 0.005 0.33 ± 0.07 n/q 0.08 0.7
Naloxone 8.6 ± 1.3 4.8 ± 0.9 8.2 ± 1.2 4.2 ± 2.3 9.2 2.5 n/q
Nor-BNI 0.12 ± 0.04 0.029 ± 0.004 0.07 ± 0.013 0.075 ± 0.036 0.1 ± 0.09 0.04 n/q
18-MC 4.5e3 ± 1.4e3 2.8e3 ± 0.6e3 2.9e3 ± 0.7e3 4.3e3 ± 1.9e3 n/d 1.8e3 n/q
n/q non-quantiﬁable. n/d not determined.
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property. Noribogaine was a partial agonist at OPRK in the [35S]
GTPgS binding stimulation assays (Fig. 2). Therefore, we set out to
determine if noribogaine was also a rival agonist that can func-
tionally compete with and reduce the activity of more efﬁcacious
agonists than itself.
Dynorphin A andmorphine concentration-response curves were
performed in the presence and absence of rival agonists nalmefene
or noribogaine at concentrations of 36-fold and 79-fold their
respective Ki (nalmefene 3 nM, noribogaine 50 mM) (Fig. 3A). Nal-
mefene readily shifted the EC50 of dynorphin A andmorphine to the
right, with a functional inhibition constant Ke of 0.077 ± 0.016 nM
and 0.11 ± 0.005 nM. Calculated Ke were within a close range of the
Ki (0.08 nM), similar to a competitive antagonist such as nor-BNI or
naloxone (Table 3, Fig. 3A). Noribogaine, on the other hand, poorly
shifted the EC50 of these agonists and the Ke estimates in theseTable 4
Bias quantiﬁcation at the kappa and mu opioid receptors. E-coupling for activation a
where p is elog10 transformation. Bias-coupling represents the relative preference of co
coupling corrected by the intrinsic assay bias (as measured with a known unbiased refere
coupling bias. Bias-efﬁcacy represents the relative efﬁcacy to preferentially activate or inh
arrestin) for activation and IMax(G-protein)/IMax(b-arrestin) for inhibition. Italics are estim
OPRK G-protein Pathway Beta-Arre
Activation e-coupling e-signal e-couplin
Dynorphin A 0.6 0.94 2.3
U69,593 1.1 1 2
Morphine 0.9 0.91 n/d
Noribogaine 1.0 0.72 0.9
60-GNTI 0.2 0.37 0.7
Nalmefene 0.9 0.35 0.6
Ibogaine 0.5 0.18 n/q
Inhibition e-coupling e-signal e-couplin
Noribogaine 1.7 0.3 0.1
60-GNTI 0.8 0.32 0.4
Nalmefene 0.0 0.7 0.6
Ibogaine 0.2 0.8 0.4
18-MC 0.1 1.0 0.7
Nor-BNI 0.1 1.0 0.5
OPRM G-protein Pathway Beta-Arr
Activation e-coupling e-signal e-coupli
[Met]-Enk 1.2 1.04 2.4
DAMGO 1.5 1 2.3
Morphine 1.5 0.8 2.6
Buprenorphine n/d 0.26 n/q
Noribogaine 1 0.094 n/q
Inhibition e-coupling e-signal e-coupli
Noribogaine 1.1 1 1.1conditions were 40 ± 16 mM and 15 ± 4 mM respectively, about 40-
fold its Ki (Table 3, Fig. 3A). Noribogaine against dynorphin A,
U69,593, morphine, and nalmefene, was an outlier rival agonist in
all instances compared to the typical partial agonist nalmefene and
antagonists like naloxone, nor-BNI, and 18-MC (Table 3, underlined
values, Fig. 3C). These data showed that noribogaine was an atypical
partial kappa agonist because it was unable to functionally sur-
mount receptor activation of other agonists of the OPRK G-protein
pathway.
In another set of experiments (Fig. 3B), noribogaine and nal-
mefene concentration-inhibition curves were produced in the
presence of more efﬁcacious agonists such as U69,593, dynorphin
A, or morphine. In the case of nalmefene, noribogaine was used as
the agonist. Nalmefene readily reduced the signal of moderate to
high concentrations of rival full (U69,593) or partial (noribogaine)
agonists to its own reduced levels (30%) with an apparent IC50nd inhibition is a measure of the coupling efﬁciency, using pKi-pEC50 and pKi-pKe,
upling between the G-protein or b-arrestin pathways and used the difference in e-
nce ligand). Underlined cells represent the reference compound for the values of the
ibit the G-protein or b-arrestin pathways and used the ratio EMax(G-protein)/EMax(b-
ate only.
stin2 Pathway Bias G-protein Vs b-arrestin
g e-signal Bias-coupling Bias-efﬁcacy
1 6.3 vs 1 1 vs 1.06
1 1 vs 1 1 vs 1
n/d n/d n/d
0.13 1 vs 630 5.5 vs 1
0.12 1 vs 2.5 3.1 vs 1
0.31 1 vs 1.5 1.13 vs 1
0.21 n/d 1 vs 1.16
g e-signal Bias-coupling Bias-efﬁcacy
0.6 1 vs 158 1 vs 2
0.69 1 vs 1.6 1 vs 2.15
0.7 1 vs 1 1 vs 1
1 1 vs 2.5 1.25 vs 1
1 1 vs 1 1 vs 1
1 1 vs 1 1 vs 1
estin2 Pathway Bias G-protein Vs b-arrestin
ng e-signal Bias-coupling Bias-efﬁcacy
1 1 vs 1 1.04 vs 1
1.02 1 vs 2.5 1 vs 1.02
0.79 1 vs 1.25 1.01 vs 1
n/d n/q n/d
0.03 n/q n/q
ng e-signal Bias-coupling Bias-efﬁcacy
1 1 vs 1 1 vs 1
Table 5
Noribogaine modulation of [35S]GTPgS binding (A) and b-Arrestin 2 recruitment (B) in CHOeK1 stably expressing human OPRM. The maximal stimulation EMax and the
functional activation constant EC50 of tested ligands [met]-enkephalin (Met-EnK), DAMGO, morphine, noribogaine, ibogaine, 18-MC, and naloxone were calculated using non-
linear regression analysis. The functional inhibition constant Ke for GTPgS assays was calculated using EC50 shifts with the equation: Ke ¼ [Inhibitor]/(DR-1) where DR is the
ratio of the agonist EC50 in the presence and the absence of inhibitor. For b-Arrestin assays, Ke was calculated from concentration-inhibition curves in the presence of agonist at
EC80 using a modiﬁed Cheng-Prusoff equation: Ke¼ [IC50]/(1þ[agonist]/EC50). Coupling efﬁciency (e-coupling, e-cpl) indicated the relationship between the apparent binding
afﬁnity Ki versus the apparent functional activation potency (EC50) or the functional inhibition potency (Ke) of a given ligand and used the equations pKi-pEC50 and pKi-pKe
where p represents a elog10 transformation.[Ϟagonist] represents the agonist that was used to produce concentration-response curves in the presence and the absence of
tested inhibitory compounds noribogaine, ibogaine, naloxone, and 18-MC. Data are shown as the mean ± SE of (n) experiments.
OPRM pKi [35S]-GTPgS binding
Activation Inhibition [ϞMet-ENK]
Ligands \ outputs EMax in % ± s.e. (n) EC50 in nM ± s.e. (n) pEC50/[e-cpl] Ke in nM ± s.e. (n) pKe/[e-cpl]
[Met]-Enk 9.2 104 ± 6 (3) 11 ± 3 (4) 8.0/[1.2] n/q n/q
DAMGO 9.1 100 (9) 27 ± 7 (9) 7.6/[1.5] n/q n/q
Morphine 9.0 80 ± 4.5 (4) 32 ± 1.2 (3) 7.5/[1.5] n/d n/d
Buprenorphine 10.1 26 ± 2.2 (2) n/d. n/d n/d n/d
Noribogainea 5.8 9.4 ± 1.8 (4) 16050 ± 9409 (4) 4.8/[1] 19846 ± 3980 (4) 4.7/[1.1]
Ibogaineb 5.2 <5 (2) n/q n/q 7957 ± 2629 (4) 5.1/[0.1]
18-MC 5.6 <5 (2) n/q n/q 5831 ± 1418 (3) 5.2/[0.4]
Naloxonec 8.9 <5 n/q n/q 1.2 ± 0.3 (2) 8.9/[0.0]
PathHunter® b-Arrestin Recruitment
[Met]-Enk 9.2 100 159 ± 38 (4) 6.8/[2.4]
DAMGOd 9.1 102 162 6.8/[2.3]
Morphined 9.0 79 411 6.4/[2.6]
Noribogaine 5.8 3 ± 0.5 (1) n/q 20040 (1) 4.7/[1.1]
n/q non-quantiﬁable. n/d not determined.
a Ke values of noribogaine were [ϞDAMGO] 19203 ± 5168 nM (n ¼ 2) and [ϞMorphine] 28467 ± 14439 nM (n ¼ 2).
b Ke values of ibogaine was [ϞDAMGO] 2614 ± 42.07 (n ¼ 2).
c Ke value of naloxone was [ϞDAMGO] 3.4 ± 0.75 (n ¼ 5). Antonio et al. (2013) reported Ke [ϞDAMGO] values of 38300 ± 1710 nM for noribogaine, 1940 ± 460 nM for
ibogaine, and 19100 ± 2970 nM for 18-MC.
d PathHuner Assay Kit reference compounds.
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ibogaine) (Fig. 3B) and a Ke consistent with its Ki (Table 3). Nor-
ibogaine reduced the signal of more efﬁcacious agonists to its own
signal (70%), but the IC50 values were high (100e300 mM range) and
the calculated Ke were consistent with poor functional inhibition.
The apparent functional activation constant (apparent EC50), of
dynorphin A, U69,593 and morphine were then estimated in the
presence of noribogaine or nalmefene (Table 3). Apparent EC50 for
all agonists tested in the presence of nalmefene were close to their
experimental EC50. However, in the presence of noribogaine,
apparent EC50 of common kappa agonists were signiﬁcantly lower
than their actual experimental EC50 (Table 3, underlined values).
This atypical phenomenon may reﬂect the stabilization of a dif-
ferential set of active receptor conformations by noribogaine
compared to other kappa agonists tested.
Altogether, these data suggest a potential protean agonism of
noribogaine, a predictive functional bias (Kenakin, 2007) that we
set to assess further.3.5. Noribogaine is a G-protein-biased kappa agonist
PathHunter b-Arrestin GPCR assays detecting the interaction of
b-arrestin 2 with the activated receptor were used to measure non-
G protein OPRK activity in CHOeK1 live cells (Violin et al., 2014).
Concentration-response curves to noribogaine were compared to
full endogenous agonist dynorphin A drug treatment (Fig. 4A).
Calculated EC50 values, maximal responses and coupling efﬁ-
ciencies are shown in Table 2B. Dynorphin A displayed an EC50 of
11 ± 2 nM at OPRK. Noribogaine exhibited a profound functional
bias at OPRK and was marginally efﬁcacious at inducing b-arrestin
recruitment with an EMax of 13 ± 3% and an estimated EC50 of
110 nM. For comparative purposes, nalmefene was tested once and
displayed an EMax of 30% as expected for this unbiased partial
agonist. EC50 and EMax values from (Schmid et al., 2013) were
collected for 60-GNTI, and showed that noribogaine was activatingat the same level as 60-GNTI. Ibogaine and 18-MC were tested once;
they did not display any bias and their pharmacological behavior
was comparable to typical kappa ligands.
The functional activation coupling efﬁciencies in the b-arrestin
assay were calculated in a similar manner as the [35S]GTPgS
binding assay and showed that dynorphin A and U69,593 displayed
a similar coupling efﬁciency of 2, reﬂecting the intrinsic assay ef-
ﬁciency (Table 2B, Fig. 4C). Noribogaine had a negative activation
coupling efﬁciency of 0.9 for the b-arrestin pathway, indicating a
profound coupling bias of 1:630 in favor of this pathway in com-
parison to the G-protein pathway (Table 4). In comparison, the
biased ligand 60-GNTI did not display activation coupling bias be-
tween the G-protein and the b-arrestin pathways (Table 4).
The activation efﬁcacy bias between the G-protein pathway and
the b-arrestin pathway was evaluated by comparing the maximal
efﬁcacy (EMax) for each pathway in comparison to reference ligand
dynorphin A or U69,593 (1e1 maximal efﬁcacies ratio) (Table 4).
Although nalmefene is a partial agonist, it did not display an acti-
vation efﬁcacy bias, reﬂecting that partial agonism is not an indi-
cation of bias per se. Both noribogaine and 60-GNTI displayed an
activation efﬁcacy bias in favor of the G-protein pathway and nor-
ibogaine was almost twice more biased than 60-GNTI (5.5e1 versus
3 to 1).3.6. Noribogaine is a barrestin-biased kappa antagonist
Because noribogaine was unable to induce the recruitment of b-
arrestin following activation of the OPRK receptors, it was then
tested for its ability to inhibit b-arrestin recruitment induced by
efﬁcacious agonists of this pathway (Fig. 4B). In these assays, b-
arrestin recruitment was induced by the endogenous agonist
dynorphin A sets at its EC80 concentration and challenged with
increasing concentrations of noribogaine. Noribogaine inhibited
dynorphin A-induced b-arrestin recruitment up to ~60%, with an
IC50 of 1 ± 0.16 mM (Fig. 4B, Table 2B). In contrast, when a similar
Fig. 4. Noribogaine is a G-protein biased agonist and a b-arrestin biased antagonist
of the kappa opioid receptors (OPRK). CHOeK1 cell membrane preparations
expressing the human OPRK receptors were used for [35S]GTPgS binding assays and
live cells were used for PathHunterR b-arrestin 2 recruitment assays. (A) Comparative
concentration-response curves of dynorphin A (DYNA) and noribogaine (NORI) in [35S]
GTPgS binding assay (black) and PathHunterR b-arrestin 2 recruitment assay (grey). (B)
Comparative noribogaine concentration-inhibition curves of DYNA set at its EC80 in
[35S]GTPgS binding assay (black) and PathHunterR b-arrestin 2 recruitment assay
(grey). (C) Representation of the b-arrestin pathway coupling activation efﬁciency for a
series of kappa agonists (log(Ki/EC50)) and of the coupling inhibition efﬁciency
against DYNA for a series of kappa antagonists and partial agonists (log(Ki/Ke)).
Clustering of data points represents the intrinsic assay efﬁciency in the current
experimental conditions of b-arrestin recruitment assay with CHO cells expressing the
human OPRK. Outlier data points (noribogaine, 60GNTI) indicate atypical pharma-
cology of certain ligands.
Fig. 3. Comparative inhibitory effects of partial agonists noribogaine and nalme-
fene on agonist-induced [35S]GTPgS binding at the kappa opioid receptors (OPRK).
(A) CHOeK1 cell membrane preparations expressing the OPRK receptors were pre-
incubated with the partial agonists nalmefene (NALM) and noribogaine (NORI), and
the pure antagonist nor-BNI at 36-fold, 79-fold, and 125-fold their respective apparent
afﬁnity Ki. Membrane preparations were then stimulated with increasing concentra-
tions of dynorphin A (DYNA) and morphine (MOR). The functional inhibition constants
Ke were calculated and compared to the ligand's respective Ki and EC50 (GTPgS) as
shown in Table 3. (B) Membrane preparations were stimulated by increasing con-
centrations of NALM or NORI in the presence of agonists U69,593 (U69- 100 nM),
morphine (MOR- 5 mM), noribogaine (NORI- 10 and 100 mM) and nalmefene (NALM-
20 nM). Dotted lines indicate the interval between the EC50 and the IC50 of tested
ligand (NALM and NORI) in the absence and the presence of 100 nM U69,593. Data are
shown as the mean ± SEM of representative experiment(s) performed in triplicate. (C)
Representation of the G-protein pathway coupling activation efﬁciency (log(Ki/EC50))
of a series of kappa agonists and of the coupling inhibition efﬁciency (log(Ki/Ke))
against dynorphin A (see Table 3 for other agonists) for a series of kappa antagonists
and partial agonists. Clustering of data points represents the intrinsic assay efﬁciency
in the current experimental conditions of [35S]GTPgS binding activation with CHO
membranes expressing the human OPRK. Outlier data points indicate atypical phar-
macology of certain ligands (noribogaine, 60-GNTI).
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on the G-protein pathwaywith dynorphin A at its EC80, noribogaine
only inhibited agonist-induced activation of the receptor by ~5%
with an IC50 of ~150 mM (Fig. 4B). Noribogaine was thus 150-fold
more potent at inhibiting dynorphin A-induced b-arrestin 2
recruitment than at inhibiting dynorphin A-induced G-protein
activation (Table 4). For comparison, typical partial agonist nal-
mefene inhibited dynorphin A-induced b-arrestin recruitment upto 70% with an approximate Ke of 0.32 nM, whereas it inhibited
dynorphin A-induced GTP-binding with a Ke of 0.08 nM and was
apparently equipotent with only a 4-fold difference. Notably, the
apparent inhibition coupling efﬁciencies for antagonists of the b-
arrestin pathway were all clustered in a 0.5 range (Fig. 4C) and
indicated that the current experimental conditions were producing
an assay slightly less sensitive to antagonists than the GTP-binding
assay (coupling efﬁciency close to 0) with a robust assay's intrinsic
Fig. 5. Noribogaine is a weak antagonist of [35S]GTPgS binding stimulation and b-arrestin recruitment at the mu receptor (OPRM). CHOeK1 cell membrane preparations
expressing the human OPRM receptors were used for [35S]GTPgS binding assays and live cells were used for PathHunterR b-arrestin 2 recruitment assays. Receptors were stimulated
by increasing concentration of agonists. (A) Comparative concentration-response curves of [met]-enkephalin (Met-Enk) and noribogaine (NORI) in [35S]GTPgS binding assay (black)
and PathHunterR b-arrestin 2 recruitment assay (grey). (B) Comparative noribogaine concentration-inhibition curves of [met]-enkephalin set at its EC80 in [35S]GTPgS binding assay
(black) and PathHunterR b-arrestin 2 recruitment assay (grey). (C, D) Concentration-response curves and EC50 shifts of [met]-enkephalin (Met-Enk), DAMGO and morphine in the
presence and absence of 15 and 150 mM noribogaine (NORI), 30 mM ibogaine (IBO), 30 mM 18-MC, and 30 nM naloxone (NALO). (AeD) Data points used for the non-linear regression
analysis are shown as the mean ± SEM of each representative experiment(s). Corresponding values of EC50, EMax, and Ke with mean ± SE for the entire set of experiments can be
found in Table 5.
E.L. Maillet et al. / Neuropharmacology 99 (2015) 675e688684coupling efﬁciency reproducibility. Finally, the inhibition efﬁcacy
bias for noribogaine was 1:2 in favor of the b-arrestin pathway,
which is similar to 60-GNTI (Table 4), whereas other antagonists
were unbiased.
3.7. Noribogaine has a marginal mu agonistic activity
[35S]GTPgS binding to membrane preparations of CHO cells
stably expressing human OPRM were examined in response to
noribogaine, ibogaine, and morphine drug treatment (Fig. 5A,
Table 5A). The prototypical full agonist DAMGO and the endoge-
nous agonist [met]-enkephalin ([met]-Enk) were used as reference
agonists. Morphine was a partial agonist with an EMax of 80 ± 4.5%
and an EC50 of 32 ± 1.2 nM. The partial agonist buprenorphine
stimulated OPRM with an EMax of 26 ± 2.2% in our assays and in
previously reported assays (Saidak et al., 2006). Noribogaine
marginally stimulated [35S]GTPgS binding to OPRM, with an EMax of
10% of the full agonist DAMGO or [met]-enkephalin (Fig. 5A,
Table 5A) and comparable to the level of activation previously re-
ported (Antonio et al., 2013). Ibogaine and 18-MC did not stimulate
the OPRM G-protein pathway. Concentration-response curves of b-
arrestin recruitment of noribogaine at the OPRM receptors were
compared to full agonist [met]-enkephalin (Fig. 5A). [Met]-
enkephalin displayed an EC50 of 159 ± 38 nM at OPRM. As ex-
pected given its marginal efﬁcacy at the G-protein pathway, nor-
ibogainewas not amu agonist of the b-arrestin pathway. Calculated
EC50 values, maximal responses and coupling efﬁciencies are
shown in Table 5.
3.8. Weak antagonistic properties of noribogaine at the mu opioid
receptor
Noribogaine marginally stimulated [35S]GTPgS binding via
OPRM with an approximate EC50 of 16 mM (Fig. 5A). Therefore, weinvestigated if noribogaine was an antagonist of OPRM. [Met]-
enkephalin, DAMGO and morphine dose responses were carried
out in the presence and absence of 15 and 150 mM of noribogaine
(Fig. 5C and D). Noribogaine was an inhibitor of all agonists tested
and shifted their EC50 to the right by a magnitude of ~1log. The
calculated functional inhibition constant (Ke) values were ~20 mM
(Table 5A, and Table 5 footer). In a similar design, naloxone dis-
played a Ke of 1.2 ± 0.3 nM, a value close to its Ki at OPRM, like its
inhibition constant at OPRK (Tables 2 and 3). On the contrary,
noribogaine was an outlier antagonist with an inhibitory coupling
efﬁciency of 1.1, while ibogaine, naloxone, and 18-MC were still
behaving like typical antagonists with clustered e-coupling values
close to 0 (Fig. 5C and Table 5A). Noribogaine was then tested for its
ability to inhibit [met]-enkephalin-induced b-arrestin-2 recruit-
ment at OPRM (Fig. 5B and Table 5B). Noribogaine inhibited agonist
responses by 80e100% with an IC50 of 100 ± 25 mM.
Regardless of the pathway tested (G-protein and b-arrestin
pathways), noribogaine displayed similar functional inhibition
constants and was an unbiased ligand of the mu opioid receptor
(Table 4), albeit an inhibitory coupling efﬁciency outlier (Table 5A/
B) in comparison to other mu antagonists. In fact, noribogaine also
decreased the EMax of [met]-enkephalin, DAMGO and morphine
(Fig. 5C and D), indicating a degree of unsurmountable antagonism
by noribogaine in functional assays. Apparent unsurmountable
antagonism can encompass several distinct molecular mechanisms
such as (a) irreversible competitive antagonism, (b) noncompeti-
tive antagonism, or (c) functional antagonism; for review (Neubig
et al., 2003).
3.9. Binding model of noribogaine and ibogaine to the inactive
conformation of the mu opioid receptor
Noribogaine showed a proﬁle of unbiased antagonist at the
OPRM and stabilized the inactive conformation of the receptor.
Fig. 6. Ligand-protein binding contacts of noribogaine with OPMR. (A) Schematic of detailed ligand atom interactions with the protein residues. Interactions that occur more
than 30.0% of the simulation time in the selected trajectory (0.00 through 12.00 ns), are shown (Note: it is possible to have interactions with >100% as some residues may have
multiple interactions of a single type with the same ligand atom. over a 12 ns molecular dynamics simulation). (B) Binding model of noribogaine in OPMR extracted from a
molecular dynamics simulation (see text, compare to A).
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inactive form of the OPRM to perform in silico binding experiments
with noribogaine.
We developed an in silico binding model based on the mouse
OPRM co-crystal structure [PMID 22437502] (Manglik et al., 2012)
as described in methods. The mouse and human OPRM share 94%
(global) sequence identity and all binding site residues are iden-
tical. After initial optimization of the model, the top docking poses
of noribogaine and ibogaine were pharmacophorically aligned with
the co-crystal morphinan antagonist as one would expect: the
hydrophobic ibogaine and noribogaine bicyclic system and ethyl
substituent with morphinan cyclopropyl residues were spatially
aligned and the positively charged tertiary amines were super-
imposed with each forming a hydrogen bond to the site chain of
Asp147. Then, the noribogaine and ibogaine OPRM complexes were
each used in a 12 ns all atom explicit water molecular dynamics
simulation (see methods). Trajectory analysis revealed the most
prevalent interactions of noribogaine (Fig. 6A) and ibogaine. Both
ligands formed a stable hydrogen bond with Asp147 via their ter-
tiary amine. Noribogaine and ibogaine formed pi-cation interaction
with Tyr148 (64% and 56%, respectively), and hydrophobic in-
teractions with His297 (64 and 93%, respectively). Further hydro-
phobic interactions were observed between Val236 (~40 and ~60%,
respectively), Tyr326 (~20 and ~40% respectively), Met151 (~20%
and ~30%, respectively) and also Trp293, Ile296, Val300. Charac-
teristically, noribogaine, but not ibogaine, formed a water bridge
with Tyr148 for 34% of the simulation time. Both ligands showed a
hydrogen bond with His297 for about 20% of the simulation.
Movies of the simulations were generated and are available as
supporting material. A representative illustration frame of nor-
ibogaine in the OPRM was extracted from the simulation and is
shown in Fig. 6B.
Supplementary data related to this article can be found online at
http://dx.doi.org/10.1016/j.neuropharm.2015.08.032.
4. Discussion
Historically, in vivo studies excluded the possibility of proto-
typical morphine-like agonistic mechanism of ibogaine and its
metabolite noribogaine at the mu and/or kappa opioid receptors
(see introduction). In the other hand, naloxone-like antagonistic
mechanisms could not be demonstrated either. These ambiguous
results lead to a gap of knowledge between the correlation of
receptor-ligand mechanistics and the intriguing and beneﬁcial ef-
fects of ibogaine and its metabolite noribogaine with opiate drugsand to the opioid system. Our current study now demonstrates that
noribogaine is in fact a G-protein biased kappa agonist, and a
weaker mu antagonist. The described potencies in our study closely
match physiologically relevant brain concentrations of therapeu-
tically effective doses of noribogaine. Thus, noribogaine's atypical
modulatory properties of the kappa opioid system, and to a certain
extend the mu opioid system, in the central nervous system (CNS)
must be taken into account for its mechanism of action in vivo.
Our study shows that noribogaine is a kappa agonist. Intrave-
nous noribogaine potently triggered the release of prolactin in rats
and it was reported that this effect was centrally mediated
(Baumann et al., 2001b). We propose that noribogaine-induced
prolactin release is mediated by central OPRK, similar to what
was described for the kappa agonist nalmefene (Bart et al., 2005).
Our data also show that noribogaine was a moderately potent mu
antagonist. Thus, noribogaine also belongs to the class of dual
agonist/antagonist kappa-mu opioid ligands. In comparison, ibo-
gaine is a more potent mu antagonist and a much weaker kappa
agonist than noribogaine. Ibogaine is metabolized to noribogaine in
mammals and, as a consequence, the acute and delayed biological
effects of ibogaine treatment can be attributed to the ibogaine-
noribogaine mixture rather than to ibogaine only (Zubaran et al.,
1999). Intermediate levels of drug-related interoceptive stimuli
generalization were observed with the mixed action opiates
SKF10,047 (79%), pentazocine (74%), nalorphine (70%), and dipre-
norphine (75%) (Helsley et al., 1998). These results provide support
to the notion that the ibogaine-noribogaine mixture could be
recognized as a mixed opioid agonist-antagonist in vivo. 18-MC was
a micro-molar non-speciﬁc competitive antagonist of the kappa
andmu receptors; however it should remain clear that noribogaine
belongs to a different class of opioid ligand than ibogaine or 18-MC.
In consequence, the in vivo effects of 18-MC, experimentally
demonstrated or hoped for, cannot rely on the pharmacological
knowledge and demonstrated effects of noribogaine on the opioid
system.
A series of studies (see introduction) described the biological
effects of noribogaine treatment in reducing the stimulating and
reinforcing properties of morphine, possessing a modest analgesic
power on its own, and having the capability to potentiatemorphine
analgesia, especially in morphine tolerant animals. Our study
shows that noribogaine inhibited b-arrestin-2 recruitment of both
mu and kappa agonists. This could to a certain extent mimic the
effects of a functional deletion of the b-arrestin-2 gene which
resulted in remarkable potentiation and prolongation of the anal-
gesic effect of morphine in mice (Bohn et al., 1999). Additionally, it
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doses devoid of observable effects on nociception (Schmauss and
Herz, 1987; Takemori et al., 1992). U50,488 also attenuated
morphine tolerance and potentiated morphine analgesia in
morphine tolerant animals at doses devoid of analgesic activity
when co-administrated with morphine (Tao et al., 1994). Taken
together, these studies show that low doses of OPRK agonists can
reduce morphine tolerance and desensitization (Sharma and
Mediratta, 2001). Future studies assessing the comparative activ-
ity of noribogaine in wild type and genetically modiﬁed opioid
receptor animal models should provide further understanding of
the contribution of the kappa receptors in the effects of
noribogaine.
Ultra-low doses of opioid antagonists (naloxone and
naltrexone), which selectively inhibit the excitatory effects of
opioid agonists, have been reported to augment systemic morphine
analgesia and inhibit the development of tolerance/physical
dependence (Powell et al., 2002). In vitro assays demonstrated that
these phenomena are reproducible at the cellular level where ultra-
low concentrations of opioid ligand effectively synergized the
binding and functional response of agonists via OPRM-OPRD het-
eromers (Gomes et al., 2011). In this regard, the moderate OPRM
inhibitory activity of noribogaine at moderate to low therapeutic
doses could be of biological relevance and warrants further inves-
tigation at the molecular level on OPRM-OPRD heteromers.
In line with their localization in the hippocampus, amygdala,
hypothalamus, striatum and spinal cord, the function of the kappa
opioid receptors are related to learning and memory, emotional
control, stress response and pain (Bruchas et al., 2010; Butelman
et al., 2012; Schwarzer, 2009). Kappa agonists hold therapeutic
potential for mood and addiction disorders, psychiatric co-
morbidities, and pain management, however they also induce un-
desirable on-target side effects such as place aversion, dysphoria
and anhedonia; and hallucinations at high doses. On the other
hand, kappa antagonists hold therapeutic potential as antidepres-
sants and anxiolytics, but may induce hyperalgesic states. Thus,
until recently, kappa ligands were not considered for therapeutic
development due to their undesirable side effects. This view
changed with the introduction of a more elaborate understanding
of ligand-receptor pharmacology and the characterization of re-
ceptor drugs exhibiting functional selectivity, for review (Violin
et al., 2014). As reviewed in (Kyle, 2013), certain opioid ligands
were reported to be G protein-biased agonists, notably at the mu
receptor, and exhibited interesting physiological properties (Rives
et al., 2012).
Recent elegant studies in rodents have mechanistically linked
the activation of p38 MAPK to stress-mediated OPRK stimulation
via the b-arrestin mediated transduction pathway (Bruchas et al.,
2007, 2006). In this frame, G-protein biased kappa agonists were
described as hypothetical analgesic drugs without aversive and
dysphoric components (Chavkin, 2011). In our study, noribogaine
exhibited a profound functional bias and was not an agonist of the
OPRK b-arrestin pathway. Therefore, noribogaine appears to carry
the prerequisite pharmacological characteristics of an analgesic
kappa opioid drug devoid of aversive and dysphoric effects which
may become important during opiate detoxiﬁcation and painful
states.
Our study also shows that noribogaine is a b-arrestin biased
kappa antagonist, more potent and efﬁcacious at inhibiting agonist-
induced signaling to this pathway than to the G-protein pathway.
At a concentration corresponding to levels in the brain of rats (e.g.
0.5e5 mM) several hours after noribogaine dosing in animals (Pearl
et al., 1997), or days after ibogaine treatment in humans (Mash
et al., 2000), noribogaine tested in vitro preserved the signaling of
dynorphin A to the G-protein pathwaywhilemarkedly inhibiting b-arrestin recruitment. Thus noribogaine in the presence of dynor-
phin was able to modulate the functional selectivity of dynorphin.
This peculiar pharmacological property could contribute to
antagonist-like anti-depressive and anxiolytic activities against
stress-induced and over-active dynorphin/kappa system, as seen
during drug dependence, drug withdrawal and cravings. This
functionally selective inhibitory kappa activity may also mediate
positive effects against stress and anxiety, and atypical depression
that will be considered in future studies.
Ligand-induced functional selectivity of otherwise unbiased
agonists was previously demonstrated for some receptors of the
GPCR family interactions with conformation-speciﬁc allosteric
modulators of the receptors (i.e. the allosteric ligand LPI805 for the
NK2 receptor (Maillet et al., 2007); for review (Kenakin, 2007)).
However, in the present study noribogaine does not appear to be an
allosteric ligand: 1) it directly competed with the binding of
orthosteric radiolabeled agonists DAMGO, U69,593; 2) it displayed
functional competitive behavior with opioid orthosteric antago-
nists in GTPgS assays; 3) it was docked to the morphinan orthos-
teric binding site of the OPRM inactive state in silico with good
stringency: in silico binding experiments provide basis for nor-
ibogaine‘s interacting moieties with the inactive conformational
state crystal structure of the mu receptor and in silico interaction
scores of noribogaine and ibogaine are congruent to their afﬁnity
ranking in in vitro radioligand assays. In fact, our data suggest that
noribogaine would induce functional selectivity to dynorphin A via
the interplay of a set of active and inactive conformational states.
Certain conformations would be easily accessible to other agonists
(e.g. the inactive conformations and active G-protein conforma-
tions) and other conformations would be energetically challenging
to populate in place of noribogaine (e.g. the non-recruiting b-
arrestin conformation).
Multiple studies provide evidence for the existence of inter-
mediate conformational states linking the inactive receptor to the
fully active receptor. Agonist binding and activation of GPCRs has
been proposed to occur through a multistep process; for review
(Kobilka, 2004). The intermediate conformational states generated
during multistep agonist binding may have unique functional
properties as it is known that GPCR can couple to different G-
proteins and also activate non-G protein dependent pathways
depending on their conformational state(s); for review (Kenakin,
2007). Interestingly, recent investigations in drug design
described an allotropic binding mode for certain OPRK agonists,
which encompassed sequential drugereceptor interaction mecha-
nisms (Munro et al., 2013). In this regard, noribogaine merits
further investigation at a deeper molecular level using discrete
drugereceptor interactions and conformational dynamic designs as
well as cellular designs to assess further these potential allotropic
binding modalities and their functional consequences.
5. Conclusion
This study shows that noribogaine is a dual ligand of both mu
and kappa opioid receptors. Noribogaine exhibits a profound G-
protein biased agonism at the opioid receptors and can modulate
dynorphin signaling via the kappa receptor. This study clariﬁes the
mechanisms of noribogaine at modulating the function of opioid
receptors at the cellular level, providing ground for explanatory
mechanisms at the opioid system in vivo as well as new avenues of
therapeutic development and applicability.
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